RÉSUMÉ
HLA-DRB1*08:126 differs from HLA-DRB1*08:04:01:01 by one nucleotide substitution in codon 152 in exon 3.
Sujet(s)
Allèles , Séquence nucléotidique , Exons , Chaines HLA-DRB1 , Test d'histocompatibilité , Analyse de séquence d'ADN , Humains , Chaines HLA-DRB1/génétique , Test d'histocompatibilité/méthodes , Analyse de séquence d'ADN/méthodes , Codon , Alignement de séquencesRÉSUMÉ
BACKGROUND AND OBJECTIVES: Immune-mediated necrotizing myopathy (IMNM) caused by antibodies against 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is an inflammatory myopathy that has been epidemiologically correlated with previous statin exposure. We characterized in detail a series of 11 young statin-naïve patients experiencing a chronic disease course mimicking a limb-girdle muscular dystrophy. With the hypothesis that HMGCR upregulation may increase immunogenicity and trigger the production of autoantibodies, our aim was to expand pathophysiologic knowledge of this distinct phenotype. METHODS: Clinical and epidemiologic data, autoantibody titers, creatine kinase (CK) levels, response to treatment, muscle imaging, and muscle biopsies were assessed. HMGCR expression in patients' muscle was assessed by incubating sections of affected patients with purified anti-HMGCR+ serum. Whole-exome sequencing (WES) with a special focus on cholesterol biosynthesis-related genes and high-resolution human leukocyte antigen (HLA) typing were performed. RESULTS: Patients, aged 3-25 years and mostly female (90.9%), presented with subacute proximal weakness progressing over many years and high CK levels (>1,000 U/L). Diagnostic delay ranged from 3 to 27 years. WES did not reveal any pathogenic variants. HLA-DRB1*11:01 carrier frequency was 60%, a significantly higher proportion than in the control population. No upregulation or mislocalization of the enzyme in statin-exposed or statin-naïve anti-HMGCR+ patients was observed, compared with controls. DISCUSSION: WES of a cohort of patients with dystrophy-like anti-HMGCR IMNM did not reveal any common rare variants of any gene, including cholesterol biosynthesis-related genes. HLA analysis showed a strong association with HLA-DRB1*11:01, previously mostly described in statin-exposed adult patients; consequently, a common immunogenic predisposition should be suspected, irrespective of statin exposure. Moreover, we were unable to conclusively demonstrate muscle upregulation/mislocalization of HMGCR in IMNM, whether or not driven by statins.
Sujet(s)
Chaines HLA-DRB1 , Hydroxymethylglutaryl-CoA reductases , Humains , Hydroxymethylglutaryl-CoA reductases/génétique , Hydroxymethylglutaryl-CoA reductases/immunologie , Femelle , Mâle , Adulte , Chaines HLA-DRB1/génétique , Jeune adulte , Enfant , Adolescent , Enfant d'âge préscolaire , Mutation , Autoanticorps/sang , Autoanticorps/immunologie , Nécrose , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/effets indésirables , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/pharmacologie , Myosite/immunologie , Myosite/génétiqueRÉSUMÉ
Antigen presentation by HLA class II molecules to CD4+ T cells is an essential step for generating antibodies to hepatitis B antigens. In this study, we investigated the association between the HLA-DRB1 gene and the status of antibodies to hepatitis B surface and e antigens. Our results revealed a significant association between the status of anti-HBsAg and HLA-DRB1*04:03 (OR = 4.11, 95% CI = 1.50-10.84, p = 0.005, Padj. = 0.05) as well as HLA-DRB1*15:01 (OR = 1.74, 95% CI = 1.20-2.50, p = 0.002, Padj. = 0.045). MHC II binding predictions and in silico docking demonstrated strong binding affinity of HBsAg peptides to these two HLA-DRB1 molecules. Conversely, the status of anti-HBeAg was inversely associated with HLA-DRB1*14:54 (OR = 0.34, 95% CI = 0.18-0.64, p = 0.001, Padj. = 0.011), and in silico analysis revealed weak binding affinity of HBeAg peptides to HLA-DRB1*14:54. In conclusion, these findings support the involvement of HLA-DRB1 in humoral immunity against HBV infection.
Sujet(s)
Allèles , Chaines HLA-DRB1 , Anticorps de l'hépatite B , Antigènes de surface du virus de l'hépatite B , Antigènes e du virus de l'hépatite virale B , Humains , Chaines HLA-DRB1/génétique , Chaines HLA-DRB1/immunologie , Antigènes de surface du virus de l'hépatite B/immunologie , Antigènes de surface du virus de l'hépatite B/génétique , Mâle , Femelle , Adulte , Anticorps de l'hépatite B/immunologie , Anticorps de l'hépatite B/sang , Antigènes e du virus de l'hépatite virale B/immunologie , Antigènes e du virus de l'hépatite virale B/génétique , Adulte d'âge moyen , Hépatite B/immunologie , Hépatite B/virologie , Jeune adulte , Liaison aux protéines , Virus de l'hépatite B/immunologie , Virus de l'hépatite B/génétique , Simulation de docking moléculaireRÉSUMÉ
BACKGROUND: Juvenile Idiopathic Arthritis (JIA) is a complex autoimmune disease and the most common chronic rheumatological disease affecting children under the age of 16. The etiology of JIA remains poorly understood, but evidence suggests a significant genetic predisposition. METHODS: We analyzed a Swedish cohort of 329 JIA patients and 728 healthy adult controls using the Illumina OmniExpress array for genotyping. HLA alleles were imputed from GWAS data using the SNP2HLA algorithm. RESULTS: Case-control analysis yielded 12 SNPs with genome-wide significant association to JIA, all located on chromosome 6 within the MHC class II gene region. Notably, the top SNP (rs28421666) was located adjacent to HLA-DQA1 and HLA-DRB1. HLA-DRB1*08:01, HLA-DQA1*04:01, and HLA-DQB1*04:02 were the haplotypes most strongly associated with an increased risk of JIA in the overall cohort. When analyzing disease specific subtypes, these alleles were associated with oligoarthritis and RF-negative polyarthritis. Within the complex linkage disequilibrium of the HLA-DRB1-DQA1-DQB1 haplotype, our analysis suggests that HLA-DRB1*08 might be the primary allele linked to JIA susceptibility. The HLA-DRB1*11 allele group was also independently associated with JIA and specifically enriched in the oligoarthritis patient group. Additionally, our study revealed a significant correlation between antinuclear antibody (ANA) positivity and specific HLA alleles. The ANA-positive JIA group showed stronger associations with the HLA-DRB1-DQA1-DQB1 haplotype, HLA-DRB1*11, and HLA-DPB1*02, suggesting a potential connection between genetic factors and ANA production in JIA. Furthermore, logistic regression analysis reaffirmed the effects of HLA alleles, female sex, and lower age at onset on ANA positivity. CONCLUSIONS: This study identified distinct genetic associations between HLA alleles and JIA subtypes, particularly in ANA-positive patients. These findings contribute to a better understanding of the genetic basis of JIA and provide insights into the genetic control of autoantibody production in ANA-positive JIA patients. This may inform future classification and personalized treatment approaches for JIA, ultimately improving patient outcomes and management of this disease.
Sujet(s)
Anticorps antinucléaires , Arthrite juvénile , Prédisposition génétique à une maladie , Polymorphisme de nucléotide simple , Humains , Arthrite juvénile/génétique , Arthrite juvénile/immunologie , Suède , Mâle , Femelle , Anticorps antinucléaires/sang , Adolescent , Enfant , Études cas-témoins , Études de cohortes , Allèles , Haplotypes , Adulte , Étude d'association pangénomique , Génotype , Chaines alpha des antigènes HLA-DQ/génétique , Chaines HLA-DRB1/génétique , Enfant d'âge préscolaire , Déséquilibre de liaisonRÉSUMÉ
Two novel HLA class II, HLA-DRB1*13:357 and HLA-DQB1*03:525, characterised in Russian individuals.
Sujet(s)
Allèles , Chaines bêta des antigènes HLA-DQ , Chaines HLA-DRB1 , Séquençage nucléotidique à haut débit , Humains , Séquençage nucléotidique à haut débit/méthodes , Chaines HLA-DRB1/génétique , Chaines bêta des antigènes HLA-DQ/génétique , Exons , Russie , Test d'histocompatibilité/méthodes , Séquence nucléotidique , Analyse de séquence d'ADN/méthodesRÉSUMÉ
HLA-DRB1*04:379N differs from HLA-DRB1*04:01:01:01 by one nucleotide substitution in codon 4 in exon 1.
Sujet(s)
Allèles , Séquence nucléotidique , Exons , Chaines HLA-DRB1 , Test d'histocompatibilité , Analyse de séquence d'ADN , Humains , Chaines HLA-DRB1/génétique , Test d'histocompatibilité/méthodes , Analyse de séquence d'ADN/méthodes , Codon , Alignement de séquencesRÉSUMÉ
Myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), long COVID (LC) and post-COVID-19 vaccine syndrome show similarities in their pathophysiology and clinical manifestations. These disorders are related to viral or adjuvant persistence, immunological alterations, autoimmune diseases and hormonal imbalances. A developmental model is postulated that involves the interaction between immune hyperactivation, autoimmune hypophysitis or pituitary hypophysitis, and immune depletion. This process might begin with a deficient CD4 T-cell response to viral infections in genetically predisposed individuals (HLA-DRB1), followed by an uncontrolled immune response with CD8 T-cell hyperactivation and elevated antibody production, some of which may be directed against autoantigens, which can trigger autoimmune hypophysitis or direct damage to the pituitary, resulting in decreased production of pituitary hormones, such as ACTH. As the disease progresses, prolonged exposure to viral antigens can lead to exhaustion of the immune system, exacerbating symptoms and pathology. It is suggested that these disorders could be included in the autoimmune/adjuvant-induced inflammatory syndrome (ASIA) because of their similar clinical manifestations and possible relationship to genetic factors, such as polymorphisms in the HLA-DRB1 gene. In addition, it is proposed that treatment with antivirals, corticosteroids/ginseng, antioxidants, and metabolic precursors could improve symptoms by modulating the immune response, pituitary function, inflammation and oxidative stress. Therefore, the purpose of this review is to suggest a possible autoimmune origin against the adenohypophysis and a possible improvement of symptoms after treatment with corticosteroid replacement therapy.
Sujet(s)
Vaccins contre la COVID-19 , COVID-19 , Syndrome de fatigue chronique , SARS-CoV-2 , Humains , COVID-19/immunologie , Syndrome de fatigue chronique/immunologie , Syndrome de fatigue chronique/étiologie , Syndrome de fatigue chronique/virologie , Vaccins contre la COVID-19/effets indésirables , Vaccins contre la COVID-19/immunologie , SARS-CoV-2/immunologie , Syndrome de post-COVID-19 , Chaines HLA-DRB1/génétique , Chaines HLA-DRB1/immunologieRÉSUMÉ
Recurrent pregnancy loss (RPL) is a major reproductive health issue with multifactorial causes, affecting 2.6% of all pregnancies worldwide. Nearly half of the RPL cases lack clinically identifiable causes (e.g., antiphospholipid syndrome, uterine anomalies, and parental chromosomal abnormalities), referred to as unexplained RPL (uRPL). Here, we perform a genome-wide association study focusing on uRPL in 1,728 cases and 24,315 female controls of Japanese ancestry. We detect significant associations in the major histocompatibility complex (MHC) region at 6p21 (lead variant=rs9263738; P = 1.4 × 10-10; odds ratio [OR] = 1.51 [95% CI: 1.33-1.72]; risk allele frequency = 0.871). The MHC associations are fine-mapped to the classical HLA alleles, HLA-C*12:02, HLA-B*52:01, and HLA-DRB1*15:02 (P = 1.1 × 10-10, 1.5 × 10-10, and 1.2 × 10-9, respectively), which constitute a population-specific common long-range haplotype with a protective effect (P = 2.8 × 10-10; OR = 0.65 [95% CI: 0.57-0.75]; haplotype frequency=0.108). Genome-wide copy-number variation (CNV) calling demonstrates rare predicted loss-of-function (pLoF) variants of the cadherin-11 gene (CDH11) conferring the risk of uRPL (P = 1.3 × 10-4; OR = 3.29 [95% CI: 1.78-5.76]). Our study highlights the importance of reproductive immunology and rare variants in the uRPL etiology.
Sujet(s)
Avortements à répétition , Prédisposition génétique à une maladie , Étude d'association pangénomique , Humains , Femelle , Avortements à répétition/génétique , Grossesse , Fréquence d'allèle , Chaines HLA-DRB1/génétique , Polymorphisme de nucléotide simple , Adulte , Allèles , Études cas-témoins , Antigènes HLA-C/génétique , Complexe majeur d'histocompatibilité/génétique , Chromosomes humains de la paire 6/génétique , Variations de nombre de copies de segment d'ADN , Haplotypes , Japon/épidémiologie , Antigènes HLA-B/génétique , Variation génétiqueRÉSUMÉ
HLA-DRB1*09:54 shows a substitution G to A at position 449 when compared with HLA-DRB1*09:01:02:01.
Sujet(s)
Allèles , Asiatiques , Exons , Chaines HLA-DRB1 , Test d'histocompatibilité , Humains , Chaines HLA-DRB1/génétique , Asiatiques/génétique , Séquence nucléotidique , Analyse de séquence d'ADN/méthodes , Substitution d'acide aminé , Alignement de séquences , Polymorphisme de nucléotide simple , Codon , Peuples d'Asie de l'EstRÉSUMÉ
To investigate the potential relationship between HLA alleles and haplotypes and the age at diagnosis of type 1 diabetes (T1DAgeD) in an admixed Brazilian population. This nationwide study was conducted in public clinics across 12 Brazilian cities. We collected demographic and genetic data from 1,600 patients with T1D. DNA samples were utilised to determine genomic ancestry (GA) and perform HLA typings for DRB1, DQA1 and DQB1. We explored allele and haplotype frequencies and GA in patients grouped by T1DAgeD categories (<6 years, ≥6-<11 years, ≥11-<19 years and ≥19 years) through univariate and multivariate analyses and primary component analyses. Additionally, we considered self-reported colour-race and identified a familiar history of T1D in first-degree relatives. The homozygosity index for DRB1~DQA1~DQB1 haplotypes exhibited the highest variation among T1DAgeD groups, and the percentages of Sub-Saharan African and European ancestries showed opposite trends in principal component analysis (PCA) analyses. Regarding the association of alleles and haplotypes with T1DAgeD, risk alleles such as HLA-DQB1*03:02g, -DQA1*03:01g, -02:01g, DRB1*04:05g and -04:02g were more frequently observed in heterozygosity or homozygosity in T1D patients with an early disease onset. Conversely, alleles such as DRB1*07:01g, -13:03g, DQB1*06:02g and DQA1*02:01 were more prevalent in older T1D patients. The combination DR3/DR4.5 was significantly associated with early disease onset. However, gender, GA, familiar history of T1D and self-reported colour-race identity did not exhibit significant associations with the onset of T1D. It is worth noting that the very common risk haplotype DRB1*03:01g~DQA1*05:01g~DQB1*02:01g did not differentiate between T1DAgeD groups. In the admixed Brazilian population, the high-risk haplotype DRB1*04:05~DQA1*03:01~DQB1*03:02 was more prevalent in individuals diagnosed before 6 years of age. In contrast, the protective alleles DQA1*01:02g, DQB1*06:02g, DRB1*07:01g and DRB1*13:03g and haplotypes DRB1*13:03g~DQA1*05:01g~DQB1*03:01g and DRB1*16:02g~DQA1*01:02g~DQB1*05:02g were more frequently observed in patients diagnosed in adulthood. Notably, these associations were independent of factors such as sex, economic status, GA, familiar history of T1D and region of birth in Brazil. These alleles and haplotypes contribute to our understanding of the disease onset heterogeneity and may have implications for early interventions when detected in association with well-known genomic risk or protection factors for T1D.
Sujet(s)
Allèles , Diabète de type 1 , Fréquence d'allèle , Haplotypes , Humains , Brésil/épidémiologie , Diabète de type 1/génétique , Diabète de type 1/épidémiologie , Diabète de type 1/diagnostic , Mâle , Femelle , Enfant , Adolescent , Adulte , Enfant d'âge préscolaire , Jeune adulte , Prédisposition génétique à une maladie , Chaines HLA-DRB1/génétique , Chaines alpha des antigènes HLA-DQ/génétique , Chaines bêta des antigènes HLA-DQ/génétique , Âge de début , Nourrisson , Adulte d'âge moyenRÉSUMÉ
Rheumatoid arthritis (RA) is prevalent in many Indigenous North American First Nations (FN) and tends to be seropositive, familial, and disabling, as well as associated with highly unfavorable outcomes such as early mortality. The risk of developing RA is based on a perfect storm of gene-environment interactions underpinning this risk. The gene-environment interactions include a high frequency of shared epitope encoding HLA alleles, particularly HLA-DRB1*1402, in the background population, and prevalent predisposing environmental factors such as smoking and periodontal disease. Together, these provide a compelling rationale for an RA prevention agenda in FN communities. Our research team has worked in partnership with several FN communities to prospectively follow the first-degree relatives of FN patients with RA, with the aim of better understanding the preclinical stages of RA in this population. We have focused on specific features of the anticitrullinated protein antibodies (ACPA) and other proteomic biomarkers as predictors of future development of RA. These studies have now led us to consider interventions having a favorable risk-benefit ratio if applied at a stage prior to a hypothetical "point of no return," when the autoimmunity potentially becomes irreversible. Based on a supportive mouse model and available human studies of curcumin, omega-3, and vitamin D supplements, we are undertaking studies where we screen communities using dried blood spot technology adapted for the detection of ACPA, and then enrolling ACPA-positive individuals in studies that use a combination of these supplements. These studies are guided by shared decision-making principles.
Sujet(s)
Polyarthrite rhumatoïde , Humains , Anticorps anti-protéines citrullinées/sang , Polyarthrite rhumatoïde/prévention et contrôle , Polyarthrite rhumatoïde/génétique , Polyarthrite rhumatoïde/immunologie , Marqueurs biologiques/sang , Interaction entre gènes et environnement , Chaines HLA-DRB1 , Indiens d'Amérique NordRÉSUMÉ
AIMS: Latent autoimmune diabetes in adults (LADA) is characterized by positive islet-associated autoantibodies including glutamic acid decarboxylase antibody (GADA), and gradual decline in insulin secretion, progressing to insulin dependency. This cross-sectional study aimed to determine whether GADA by enzyme-linked immunosorbent assay (GADA-ELISA) titer of ≥180 U/mL could be associated with decline in ß-cell function in participants with LADA. METHODS: Sixty-three participants with LADA were recruited and an association between insulin secretion capacity and disease duration was investigated. Insulin peptide-specific inflammatory immunoreactivity was investigated to determine the disease's activity. RESULTS: There was a significant inverse correlation between disease duration and C-peptide index in participants with GADA-ELISA titer of ≥180 U/mL (Spearman's r (rs) = -0.516, p < 0.01). The positivity rate of insulin peptide-specific inflammatory immunoreactivity was significantly higher in those with ≥180 U/mL than in those with <180 U/mL (p < 0.05). In participants with human leukocyte antigen (HLA)-DRB1*04:05, a significant inverse correlation was observed between disease duration and C-peptide index in those with ≥180 U/mL (rs = -0.751, p < 0.01). CONCLUSIONS: GADA-ELISA titer of ≥180 U/mL, especially with HLA-DRB1*04:05, might reflect higher disease activity and may be associated with decline in ß-cell function over time and future insulin dependency in LADA.
Sujet(s)
Autoanticorps , Glutamate decarboxylase , Cellules à insuline , Insuline , Diabète auto-immun latent de l'adulte , Humains , Glutamate decarboxylase/immunologie , Mâle , Femelle , Études transversales , Autoanticorps/sang , Adulte , Adulte d'âge moyen , Cellules à insuline/immunologie , Cellules à insuline/métabolisme , Diabète auto-immun latent de l'adulte/immunologie , Diabète auto-immun latent de l'adulte/sang , Insuline/sang , Peptide C/sang , Diabète de type 1/immunologie , Diabète de type 1/sang , Chaines HLA-DRB1/génétique , Sujet âgéRÉSUMÉ
Thrombotic thrombocytopenic purpura (TTP) is one of the rare group disorders classified as thrombotic microangiopathies (TMAs). Approximately 90% of TTP developed immune-mediation by the formation of antibodies against the enzyme ADAMTS-13. The exact cause is unknown. To establish an association between human leukocyte antigen (HLA) and autoimmune basis, as susceptibility or protection against the disease, we contributed a study aiming to evaluate the role of HLA in immune-mediated TTP (iTTP). Considering epidemiological factors such as age, sex, ethnicity, and geographical origins, we contributed the study in our country, Turkey, which consist of a very heterogeneous population. Patients' data collection was retrospectively from electronic database on two University hospitals having big therapeutic apheresis service. Control arm was healthy people registered as stem cell donors matched in terms of age and sex. The frequency of HLA-DRB1 and HLA-DQB1 alleles between acquired TTP and the control group was compared using the chi-square method. Yates correction and logistic regression were performed on these results. A total of 75 iTTP patients and 150 healthy individuals enrolled to the study. HLA-DRB1∗11, HLA-DQB1∗03, HLA-DRB1∗11:01, HLA-DRB1∗14:01, HLA-DRB1∗13:05, HLA-DRB1∗11 + HLA-DQB1∗03 allele pair and HLA-DRB1∗15 + HLA- DQB1∗06 were proved to be susceptibility allele pairs for iTTP. HLA-DRB1∗15, HLA-DRB1∗01:01, HLA-DRB1∗07:01, HLA-DRB1∗13:01, HLA-DRB1∗14:54, HLA-DQB1∗05:01, HLA-DQB1∗02:02 and HLA-DRB1∗07 + HLA-DQB1∗02 allele pair were found to be protective against iTTP. Our findings support an association with iTTP across very heterogenous populations in Turkey.
Sujet(s)
Allèles , Chaines HLA-DRB1 , Purpura thrombotique thrombocytopénique , Humains , Turquie/épidémiologie , Purpura thrombotique thrombocytopénique/génétique , Purpura thrombotique thrombocytopénique/immunologie , Femelle , Mâle , Adulte , Adulte d'âge moyen , Chaines HLA-DRB1/génétique , Études rétrospectives , Chaines bêta des antigènes HLA-DQ/génétique , Études cas-témoins , Fréquence d'allèle , Prédisposition génétique à une maladie , Jeune adulte , Antigènes HLA/génétique , AdolescentRÉSUMÉ
HLA-mismatched unrelated donors and haploidentical related donors are suitable stem cell sources for hematopoietic cell transplantation (HCT) when patients lack HLA-matched donors. Clinical outcome after mismatched HCT is influenced by HLA factors including the similarity of peptide-binding motifs (PBMs) between the patient and unrelated donor, and of the HLA-B leader in unrelated and haploidentical donors. Whether these factors can aid in the selection between mismatched unrelated and haploidentical donors is not known. To address this question, we investigated outcomes between the two donor types defined by matching for the PBM and leader peptide. We compared PBM-matched (n = 614) and mismatched (n = 958) MMUDs with calcineurin-inhibitor-based prophylaxis to four haploidentical groups that received post-transplant cyclophosphamide (PTCy)-based prophylaxis. The haploidentical groups were B-leader matched/DRB1-mismatched (n = 722), B-leader matched/DRB1-matched (n = 154), B-leader mismatched/DRB1-mismatched (n = 493), and B-leader mismatched/DRB1-matched (n = 63). Multivariate analysis showed that the B-leader matched/DRB1-mismatched haploidentical group had the best overall survival (OS) compared to the PBM-matched MMUD, while other haploidentical groups had comparable OS. The PBM-mismatched MMUD showed the poorest outcomes, similar to the B-leader mismatched/DRB1-matched haploidentical group. Among non-HLA factors, donor age was the most significant predictor of OS. These results suggest that a B-leader matched/DRB1 mismatched haploidentical donor might be the preferred choice among donors of similar age. If such a donor is not available, the youngest donor from either PBM-matched unrelated or other haploidentical groups could be a beneficial choice. These findings need validation with both donor groups receiving PTCy-based graft-versus-host disease prophylaxis.
Sujet(s)
Transplantation de cellules souches hématopoïétiques , Donneurs non apparentés , Humains , Transplantation de cellules souches hématopoïétiques/méthodes , Adulte , Adulte d'âge moyen , Femelle , Mâle , Adolescent , Facteurs âges , Enfant d'âge préscolaire , Test d'histocompatibilité , Greffe haplo-identique , Sujet âgé , Enfant , Maladie du greffon contre l'hôte/prévention et contrôle , Jeune adulte , Antigènes HLA/immunologie , Nourrisson , Cyclophosphamide/usage thérapeutique , Chaines HLA-DRB1/génétiqueRÉSUMÉ
The HLA region, especially HLA class I and II genes, which encode molecules for antigen presentation to T cells, plays a major role in the predisposition to autoimmune disorders. To clarify the mechanisms behind this association, we examined genome-wide DNA methylation by microarrays to cover over 850,000 CpG sites in the CD4+ T cells and CD19+ B cells of healthy subjects homozygous either for DRB1*15-DQA1*01-DQB1*06:02 (DR2-DQ6, n = 14), associated with a strongly decreased T1D risk, DRB1*03-DQA1*05-DQB1*02 (DR3-DQ2, n = 19), or DRB1*04:01-DQA1*03-DQB1*03:02 (DR4-DQ8, n = 17), associated with a moderately increased T1D risk. In total, we discovered 14 differentially methylated CpG probes, of which 10 were located in the HLA region and six in the HLA-DRB1 locus. The main differences were between the protective genotype DR2-DQ6 and the risk genotypes DR3-DQ2 and DR4-DQ8, where the DR2-DQ6 group was hypomethylated compared to the other groups in all but four of the differentially methylated probes. The differences between the risk genotypes DR3-DQ2 and DR4-DQ8 were small. Our results indicate that HLA variants have few systemic effects on methylation and that their effect on autoimmunity is conveyed directly by HLA molecules, possibly by differences in expression levels or function.
Sujet(s)
Ilots CpG , Méthylation de l'ADN , Diabète de type 1 , Prédisposition génétique à une maladie , Génotype , Humains , Diabète de type 1/génétique , Diabète de type 1/immunologie , Lymphocytes T CD4+/immunologie , Lymphocytes T CD4+/métabolisme , Lymphocytes B/immunologie , Lymphocytes B/métabolisme , Femelle , Mâle , Chaines HLA-DRB1/génétique , Chaines HLA-DRB1/immunologie , AllèlesRÉSUMÉ
PURPOSE: Case reports of subacute thyroiditis (SAT) following coronavirus disease-19 (COVID-19) have been reported. Because the relationship between SAT and human leucocyte antigen (HLA) alleles is known, we aimed to determine HLA alleles that may predispose a patient to coronavirus infection and/or post-COVID-19 SAT. METHOD: This retrospective study was conducted in 51 patients with SAT and 190 healthy bone marrow donor volunteers. HLA-A, -B, -C, -DRB1, and -DQB1 were genotyped using next-generation sequencing. The study population was grouped into four groups according to SAT and COVID-19 history. RESULTS: The frequency of HLA-DQB1*04:02 was higher in the COVID-19(-) participants than in the COVID-19(+) participants (=0.045). The presence of HLA-DQB1*04:02 was associated with a lower risk of developing COVID-19 in all groups. The frequencies of HLA-B*35:01, HLA-B*35:03, HLA-DRB1*12:01, and HLA-DRB1*14:01 were different in the SAT(+) group than in the SAT(-) group in COVID-19(-) group. The frequencies of HLA-C*12:03, HLA-DQB1*06:04, HLA-DRB1*13:02, and HLA-DRB1*13:03 were different in the SAT(+) group than in the SAT(-) group in the COVID-19 (+) group. The difference in the frequency of these HLA types remains significant when the four groups are included together as follows: In the COVID-19(+) group, the frequencies of HLA-DRB1*13:02, and HLA-DRB1*13:03 were higher in the SAT(+) group than in the SAT(-) group. In the COVID-19(-) group, the frequencies of HLA-B*35:03, HLA-DRB1*12:01, and HLA-DRB1*14:01 were higher in the SAT (+) group than in the SAT(-) group. CONCLUSION: HLA alleles associated with SAT susceptibility may vary with COVID-19 history.
Sujet(s)
COVID-19 , Fréquence d'allèle , Prédisposition génétique à une maladie , SARS-CoV-2 , Thyroïdite subaigüe , Humains , COVID-19/immunologie , COVID-19/génétique , Thyroïdite subaigüe/génétique , Thyroïdite subaigüe/immunologie , Mâle , Femelle , Adulte d'âge moyen , Études rétrospectives , Adulte , SARS-CoV-2/immunologie , Antigènes HLA/génétique , Antigènes HLA/immunologie , Allèles , Sujet âgé , Génotype , Chaines bêta des antigènes HLA-DQ/génétique , Chaines HLA-DRB1/génétiqueRÉSUMÉ
The prerequisite for successful HLA genotyping is the integrity of the large allele reference database IPD-IMGT/HLA. Consequently, it is in the laboratories' best interest that the data quality of submitted novel sequences is high. However, due to its long and variable length, the gene HLA-DRB1 presents the biggest challenge and as of today only 16% of the HLA-DRB1 alleles in the database are characterized in full length. To improve this situation, we developed a protocol for long-range PCR amplification of targeted HLA-DRB1 alleles. By subsequently combining both long-read and short-read sequencing technologies, our protocol ensures phased and error-corrected sequences of reference grade quality. This dual redundant reference sequencing (DR2S) approach is of particular importance for correctly resolving the challenging repeat regions of DRB1 intron 1. Until today, we used this protocol to characterize and submit 384 full-length HLA-DRB1 sequences to IPD-IMGT/HLA.
Sujet(s)
Allèles , Bases de données génétiques , Chaines HLA-DRB1 , Chaines HLA-DRB1/génétique , Humains , Réaction de polymérisation en chaîne/méthodes , Analyse de séquence d'ADN/méthodes , Génotype , Test d'histocompatibilité/méthodesRÉSUMÉ
Autoimmune diseases of the central nervous system (CNS) such as multiple sclerosis (MS) are only partially represented in current experimental models and the development of humanized immune mice is crucial for better understanding of immunopathogenesis and testing of therapeutics. We describe a humanized mouse model with several key features of MS. Severely immunodeficient B2m-NOG mice were transplanted with peripheral blood mononuclear cells (PBMCs) from HLA-DRB1-typed MS and healthy (HI) donors and showed rapid engraftment by human T and B lymphocytes. Mice receiving cells from MS patients with recent/ongoing Epstein-Barr virus reactivation showed high B cell engraftment capacity. Both HLA-DRB1*15 (DR15) MS and DR15 HI mice, not HLA-DRB1*13 MS mice, developed human T cell infiltration of CNS borders and parenchyma. DR15 MS mice uniquely developed inflammatory lesions in brain and spinal cord gray matter, with spontaneous, hCD8 T cell lesions, and mixed hCD8/hCD4 T cell lesions in EAE immunized mice, with variation in localization and severity between different patient donors. Main limitations of this model for further development are poor monocyte engraftment and lack of demyelination, lymph node organization, and IgG responses. These results show that PBMC humanized mice represent promising research tools for investigating MS immunopathology in a patient-specific approach.